Abviris is a pioneer in HPV serology, developing innovative, next generation, products such as Prevo-Check® for early detection and post-treatment monitoring of HPV-induced tumors. Prevo-Check® makes it possible to easily detect precancerous lesions from a drop of blood, thereby helping patients to improve their quality of life and chances of survival.
NEWS RELEASE Media Contact: Jennie Wilde, Carver Wilde Communications t: +44 (0) 7799 412230/ +44 (0)203 814 8445 e: FOR IMMEDIATE RELEASE Abviris attracts almost 2M Euros to boost HPV cancer biomarker expansion Clinical study shows efficacy of novel lateral flow test AHRENSBURG, Germany (March 16, 2021) – Existing investors in […]
Weiterlesen »NEWS RELEASE Media Contact: Jennie Wilde, Carver Wilde Communications t: +44 (0) 7799 412230/ +44 (0)203 814 8445 e: FOR IMMEDIATE RELEASE Biotech innovator Abviris appoints new leader to drive business expansion Diagnostics industry expert Dr Roman Niedbal joins as CEO AHRENSBURG, Germany (December 16, 2020) –Abviris Deutschland GmbH has appointed […]
Weiterlesen »NEWS RELEASE Media Contact: Jennie Wilde, Carver Wilde Communications t: +44 (0) 7799 412230/ +44 (0)203 814 8445 e: FOR IMMEDIATE RELEASE ‘Pinprick’ biomarker blood test offers diagnostic potential in HPV-related cancers Study shows rising antibody levels predict the course of cancer AHRENSBURG, Germany (November 10, 2020) – A potential breakthrough in the […]
Weiterlesen »We are looking forward to meeting you at the Abviris booth #52.
October 28 - October 30 at Congress Center Rosengarten